Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
P
Paglialunga, Sabina
Celerion
PII-028
-
NO PHOTOTOXICITY OR PHOTOALLERGY EFFECT WITH MRX-5LBT (10%) LIDOCAINE PATCH ADMINISTRATION
Sabina Paglialunga
Favorite
PII-032
-
WHAT TO EXPECT FROM A PHENYTOIN DRUG-DRUG INTERACTION STUDY: ADVERSE EVENT PROFILING AND SAFETY ASSESSMENT
Sabina Paglialunga
Favorite
Paice, Kelli
Cincinnati Children's Hospital Medical Center
PII-112
-
EARLY MEROPENEM PHARMACOKINETICS AND TARGET ATTAINMENT IN CHILDREN WITH SEVERE VS NON-SEVERE SEPSIS
Kelli Paice
Favorite
Paleja, Bhairav
Vantage Research
PII-018
-
CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPIES USING A MULTI-SCALE QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) PLATFORM MODEL
Bhairav Paleja
Favorite
Pallikonda Chakravarthy, Seshasai
Vantage Research
PII-216
-
EXPANDING THE SCOPE OF AN EXISTING QSP MODEL OF CD3 BISPECIFICS TO CREATE A PLATFORM MODEL FOR HEMATOLOGICAL MALIGNANCIES FOR CLINICAL APPLICATIONS
Seshasai Pallikonda Chakravarthy
Favorite
Pan, Xian
Certara, Simcyp
PII-167
-
DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESMETHYLVENLAFAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS
Xian Pan
Favorite
PII-170
-
EXPOSURE OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN LACTATING MOTHERS AND THEIR INFANTS: INSIGHTS FROM A PBPK MODEL
Xian Pan
Favorite
Park, Hyunseo
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Sciences Center
PII-214
-
DEVELOPMENT OF A MECHANISTIC CK-PD MODEL TO QUANTITATIVELY CHARACTERIZE A CD19 DIRECTED CAR-T CELL THERAPY PRODUCT DEVELOPED USING RAPID MANUFACTURING
Hyunseo Park
Favorite
PT-016
-
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Hyunseo Park
Favorite
PWII-004
-
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Hyunseo Park
Favorite
Park, Seo Yeong
Chung-buk National University College of Medicine and Hospital
PII-113
-
EFFECTS OF RENAL FUNCTION AND FOOD ON PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS OF EPAMINURAD.
Seo Yeong Park
Favorite
PII-130
-
PHARMACOKINETIC EVALUATIONS TO COMPARE FIXED-DOSE OF ENAVOGLIFLOZIN/GEMIGLIPIN 0.3/50 MG AND THE CORRESPONDING LOOSE-DOSE COMBINATION, AND TO ASSESS FOOD EFFECTS ON ENAVOGLIFLOZIN IN HEALTHY SUBJECTS.
Seo Yeong Park
Favorite
Parrott, Neil
F Hoffmann LaRoche
PII-169
-
EVALUATION OF THE POTENTIAL IMPACT ON PHAMACOKINETICS OF VARIOUS CYTOCHROME P450 SUBSTRATES OF INCREASING IL-6 LEVELS FOLLOWING ADMINISTRATION OF THE T-CELL BISPECIFIC ENGAGER GLOFITAMAB
Neil Parrott
Favorite
Pavia, Kathryn
Cincinnati Children's Hospital Medical Center
PII-204
-
NEUROLOGIC CONCERNS IN CRITICALLY ILL CHILDREN RECEIVING CEFEPIME
Kathryn Pavia
Favorite
Piscitelli, Joseph
Pfizer, Inc.
PII-046
-
AN EVALUATION OF THE DRUG INTERACTION POTENTIAL OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS
Joseph Piscitelli
Favorite
Polepally, Akshanth
Abbvie Inc.
PII-065
-
POPULATION PHARMACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
Akshanth Polepally
Favorite
Popescu, Vlad
Mayo Clinic
PII-197
-
CLINICAL EFFECTS OF MEDICAL CANNABIS FOR POST-TRAUMATIC STRESS DISORDER (PTSD) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS - A RETROSPECTIVE COHORT STUDY BASED ON MINNESOTA'S MEDICAL CANNABIS REGISTRY.
Vlad Popescu
Favorite
Powell, Nick
Indiana University School of Medicine, Division of Clinical Pharmacology
PII-078
-
EVALUATION OF G6PD ACTIVITY IN ALL OF US
Nick Powell
Favorite
Power-Hays, Alexandra
Cincinnati Children's Hospital, Division of Hematology
PII-034
-
THE FEASIBILITY OF PHARMACOKINETIC-GUIDED HYDROXYUREA DOSING FOR CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA: ANALYSIS OF THE ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT) TRIAL.
Alexandra Power-Hays
Favorite
Punwani, Naresh
Incyte Research Institute
PII-092
-
A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECTS AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099318 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Naresh Punwani
Favorite
PII-094
-
A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Naresh Punwani
Favorite
